Compare EMBJ & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBJ | NBIX |
|---|---|---|
| Founded | 1969 | 1992 |
| Country | Brazil | United States |
| Employees | 25037 | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 13.2B |
| IPO Year | N/A | 1996 |
| Metric | EMBJ | NBIX |
|---|---|---|
| Price | $64.11 | $174.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 22 |
| Target Price | $84.00 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | N/A | $24.73 |
| Revenue Next Year | $13.60 | $13.14 |
| P/E Ratio | $159.30 | ★ $91.20 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $53.56 | $122.14 |
| 52 Week High | $80.75 | $174.38 |
| Indicator | EMBJ | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 61.28 | 68.22 |
| Support Level | $60.48 | $153.96 |
| Resistance Level | $65.81 | N/A |
| Average True Range (ATR) | 1.78 | 4.45 |
| MACD | 0.54 | 0.52 |
| Stochastic Oscillator | 92.45 | 99.37 |
Embraer SA based in Sao Paulo, Brazil, manufacturer of jets. Its focus is to achieve customer satisfaction with and services addressing the commercial airline, executive jets, and defense and security markets. It has developed a customer-centric technology-driven portfolio of commercial aviation products and services that allows it to build long-term relationships with clients in the commercial aviation, executive jets, and defense and security markets. It operates through the various segments namely Commercial Aviation, Defense and Security, Executive Aviation, Service and Support, and Other Segments. The company generates maximum revenue from the Commercial Aviation segment. Geographically, the company operates in Brazil, Europe, Asia Pacific, North America, and Others.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.